Janux Therapeutics, Inc.

JANX

Janux Therapeutics, Inc.

JANX

Insider Sentiment (TTM):

Last Purchase:2025-03-07Last Sale:2026-06-02Shares Purchased (TTM):0Shares Sold (TTM):48,461

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:58,203,425Shares Outstanding:62,665,717Institutional Ownership Pct.:92.88%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	28	52	52	48	52	74	431	27	15	213	19	17
Accounts Receivable Net Current	-	-	-	-	-	-	-	-	8	1	-	-
Receivables Net Current	0	35	-	-	-	-	-	-	-	-	-	-
Short Term Investments	943	905	914	941	944	940	595	631	632	439	325	333
Prepaid Expense And Other Assets Current	12	11	9	9	10	9	8	8	8	6	5	5
Assets Current	983	1,002	976	998	1,006	1,023	1,034	666	662	659	349	355
Restricted Cash Noncurrent	1	1	1	1	1	1	1	1	1	1	1	1
Property Plant And Equipment Net	3	4	4	4	5	5	5	5	6	7	7	7
Operating Lease Right Of Use Asset	17	18	18	19	18	19	19	20	20	20	21	21
Other Assets Noncurrent	3	4	3	3	3	3	3	3	3	3	3	2
Assets	1,008	1,028	1,002	1,025	1,032	1,051	1,062	695	691	689	380	387
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	3	5	3	3	2	4	2	1	2	2	3
Accrued Liabilities Current	20	15	18	22	16	13	12	13	9	6	7	7
Contract With Customer Liability Current	35	38	-	-	-	-	0	0	0	1	2	4
Operating Lease Liability Current	3	2	2	2	2	2	2	2	2	2	2	1
Liabilities Current	60	59	25	28	21	18	17	17	12	11	13	14
Contract With Customer Liability Noncurrent	1	9	-	-	-	-	-	-	-	-	0	0
Operating Lease Liability Noncurrent	18	19	20	20	20	21	21	22	22	23	23	23
Liabilities	80	87	45	48	42	38	39	39	34	33	36	38
Stockholders Equity
Preferred Stock Value	0	0	-	-	-	-	-	-	-	-	-	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	1,328	1,317	1,304	1,291	1,282	1,270	1,258	866	849	840	512	507
Accumulated Other Comprehensive Income Loss Net Of…	-2	1	4	5	4	4	2	8	-2	-1	1	-1
Retained Earnings Accumulated Deficit	-398	-376	-351	-319	-295	-261	-238	-218	-189	-184	-169	-157
Stockholders Equity	928	942	957	977	991	1,012	1,023	656	658	656	344	349
Liabilities And Stockholders Equity	1,008	1,028	1,002	1,025	1,032	1,051	1,062	695	691	689	380	387
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	61	61	60	60	59	59	59	52	52	52	46	46
Shares Outstanding	61	61	60	60	59	59	59	52	52	52	46	46

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.34%	2.75%	5.43%	-	-	-	-	-	-	-	-	-
2025	-9.75%	-12.21%	-1.55%	0.62%	2.88%	10.27%	18.95%	-50.28%	-48.33%	1.88%	14.64%	0.65%
2024	-3.38%	-24.35%	-20.55%	33.13%	31.06%	51.35%	-17.64%	-1.44%	-19.64%	-6.47%	-7.25%	-24.15%
2023	-	-	-	-7.25%	-15.08%	-49.28%	37.80%	63.57%	42.23%	-5.43%	19.04%	13.97%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	16.35	17.01	39.04	35.86	47.03	58.47	59.21	38.80	57.34	62.09	26.80	24.55
Quick Ratio	16.14	16.83	38.67	35.54	46.59	57.94	58.72	38.32	56.63	61.48	26.40	24.17
Working Capital	923.19M	943.13M	950.89M	970.26M	984.17M	1.01B	1.02B	649.15M	650.39M	648.06M	336.21M	340.72M
Leverage & Debt
Debt to Equity	0.09	0.09	0.05	0.05	0.04	0.04	0.04	0.06	0.05	0.05	0.10	0.11
Debt Ratio	0.08	0.08	0.04	0.05	0.04	0.04	0.04	0.06	0.05	0.05	0.09	0.10
Efficiency & Turnover
Asset Turnover TTM	0.02	0.01	0.01	0.01	0.00	0.01	0.01	0.02	0.03	0.01	0.02	0.02
Days Sales Outstanding TTM	2.27	930.24	-	-	-	-	-	-	180.97	31.78	-	-
Receivables Turnover TTM	161.07	0.39	-	-	-	-	-	-	2.02	11.48	-	-
Per Share Metrics
Diluted EPS TTM	-1.63	-1.83	-1.83	-1.64	-1.71	-1.26	-1.28	-1.11	-0.81	-1.13	-1.32	-1.37
Free Cash Flow Per Share TTM	-0.74	-1.25	-1.34	-0.87	-0.70	-0.75	-0.82	-0.69	-0.88	-1.09	-1.19	-1.22
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-598.15%	-1,143.11%	-1,576.67%	-1,442.88%	-33,002.05%	-1,216.61%	-933.58%	-658.76%	-435.86%	-999.85%	-902.87%	-887.07%
Net Profit Margin TTM	-427.47%	-833.60%	-1,136.25%	-1,018.95%	-24,064.01%	-832.71%	-651.62%	-463.91%	-291.17%	-762.92%	-721.18%	-739.34%
Growth Metrics
Net Revenue Growth (1Y)	5,366.97%	47.10%	-5.55%	-23.37%	-97.10%	28.12%	30.99%	54.12%	94.86%	-19.67%	-6.14%	9.07%
Net Income Growth (1Y)	-2.89%	47.25%	64.69%	68.32%	139.85%	39.84%	18.36%	-3.30%	-34.97%	-17.16%	-7.56%	-0.15%
EPS Growth (1Y)	-4.48%	45.20%	42.85%	48.25%	110.98%	11.00%	-3.08%	-19.09%	-50.03%	-29.46%	-12.91%	-9.29%
Valuation Metrics
P/E TTM	-9.42	-7.61	-7.53	-14.88	-13.54	-21.46	-41.71	-41.00	-51.79	-33.22	-8.10	-7.36
P/B TTM	1.04	0.93	0.89	1.55	1.44	1.65	2.81	3.78	3.47	2.82	1.37	1.32
P/S TTM	40.28	63.43	85.51	151.59	3,257.28	178.70	271.80	190.19	150.79	253.43	58.43	54.42
Market Cap	966.72M	871.05M	855.14M	1.52B	1.43B	1.67B	2.88B	2.48B	2.28B	1.85B	472.29M	460.74M
Enterprise Value	938.95M	819.23M	802.81M	1.47B	1.38B	1.59B	2.45B	2.46B	2.27B	1.63B	453.09M	443.59M
Calculated Values
Free Cash Flow TTM	-46.85M	-78.49M	-83.28M	-54.00M	-43.31M	-46.53M	-44.17M	-37.82M	-47.75M	-53.26M	-52.43M	-55.98M
Net Debt	-27.77M	-51.83M	-52.33M	-48.39M	-52.45M	-73.74M	-430.61M	-26.75M	-14.66M	-212.80M	-19.21M	-17.15M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-02Sale

Owner: Doyle, Janeen Noel

Title: Chief Corp. & Bus. Dev. Ofcr

Shares: 4,059

Price/Share: $14.03

Value: $56,947.77

Shares Owned: 75,941

Relationship: Officer

Ownership: Direct

2026-05-11Sale

Owner: Dobek, Maria

Title: Vice President, Accounting

Shares: 2,038

Price/Share: $14.17

Value: $28,878.46

Shares Owned: 32,270

Relationship: Officer

Ownership: Direct

2026-01-02Sale

Owner: Mciver, Zachariah

Title: Chief Medical Officer

Shares: 2,714

Price/Share: $13.73

Value: $37,263.22

Shares Owned: 23,286

Relationship: Officer

Ownership: Direct

2026-01-02Sale

Owner: Campbell, David Alan

Title: President and CEO

Shares: 8,072

Price/Share: $13.73

Value: $110,828.56

Shares Owned: 284,982

Relationship: Director,Officer

Ownership: Direct

2026-01-02Sale

Owner: Diraimondo, Thomas

Title: Chief Scientific Officer

Shares: 2,505

Price/Share: $13.73

Value: $34,393.65

Shares Owned: 124,425

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-02	Doyle, Janeen Noel	Officer	Chief Corp. & Bus. Dev. Ofcr	Direct	Sale	4,059	14.03	$56,947.77	75,941	4
2026-05-11	Dobek, Maria	Officer	Vice President, Accounting	Direct	Sale	2,038	14.17	$28,878.46	32,270	4
2026-01-02	Mciver, Zachariah	Officer	Chief Medical Officer	Direct	Sale	2,714	13.73	$37,263.22	23,286	4
2026-01-02	Campbell, David Alan	Director,Officer	President and CEO	Direct	Sale	8,072	13.73	$110,828.56	284,982	4
2026-01-02	Diraimondo, Thomas	Officer	Chief Scientific Officer	Direct	Sale	2,505	13.73	$34,393.65	124,425	4
2026-01-02	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	1,879	13.73	$25,798.67	83,095	4
2026-01-02	Winter, Charles M.	Officer	Chief Technical Officer	Direct	Sale	2,401	13.73	$32,965.73	77,721	4
2026-01-02	Dobek, Maria	Officer	Vice President, Accounting	Direct	Sale	1,462	13.73	$20,073.26	15,373	4
2025-12-01	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	3,333	33.18	$110,588.94	84,974	4
2025-11-14	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	3,333	30.00	$99,990.00	84,974	4
2025-10-28	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	16,665	30.06	$500,949.90	82,139	4
2025-05-01	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	3,333	32.28	$107,589.24	82,139	4
2025-04-21	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	3,334	30.00	$100,020.00	82,139	4
2025-03-07	Ra, Capital Healthcare Fu…	Director	-	Indirect	Purchase	110,206	31.02	$3,418,590.12	10,141,287	4
2025-03-03	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	3,334	32.36	$107,888.24	82,139	4
2025-02-03	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	3,334	42.82	$142,761.88	82,139	4
2025-01-07	Campbell, David Alan	Director,Officer	President and CEO	Direct	Sale	5,000	60.00	$300,000.00	293,054	4
2025-01-02	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	13,334	55.64	$741,903.76	82,139	4
2024-12-24	Campbell, David Alan	Director,Officer	President and CEO	Direct	Sale	25,000	56.19	$1,404,750.00	217,054	4
2024-12-03	Campbell, David Alan	Director,Officer	President and CEO	Direct	Sale	15,000	67.00	$1,005,000.00	242,054	4
2024-11-25	Campbell, David Alan	Director,Officer	President and CEO	Direct	Sale	25,000	51.74	$1,293,500.00	257,054	4
2024-10-28	Campbell, David Alan	Director,Officer	President and CEO	Direct	Sale	25,000	53.58	$1,339,500.00	282,054	4
2024-10-18	Avalon, Bioventures Spv I…	TenPercentOwner	-	Direct	Sale	660,018	48.74	$32,169,277.32	2,071,799	4
2024-10-18	Kolchinsky, Peter, Ra Cap…	Director,TenPercentOwner	-	Indirect	Purchase	1,200,000	44.75	$53,700,000.00	9,317,246	4
2024-09-30	Avalon, Bioventures I, Lp…	TenPercentOwner	-	Direct	Sale	958	46.24	$44,297.92	6,887	4
2024-09-27	Campbell, David Alan	Director,Officer	President and CEO	Direct	Sale	25,000	46.93	$1,173,250.00	307,054	4
2024-09-27	Diraimondo, Thomas	Officer	Chief Scientific Officer	Direct	Sale	5,000	46.72	$233,600.00	97,938	4
2024-09-27	Meyer, Andrew Hollman	Officer	Chief Business Officer	Direct	Sale	50,000	45.96	$2,298,000.00	67,592	4
2024-09-13	Lichter, Jay	TenPercentOwner	-	Direct	Sale	3,815	46.68	$178,084.20	7,000	4
2024-09-12	Avalon, Bioventures I, Lp…	TenPercentOwner	-	Direct	Sale	158,031	47.00	$7,427,457.00	2,959,175	4
2024-09-09	Avalon, Bioventures I, Lp…	TenPercentOwner	-	Direct	Sale	2,182	42.33	$92,364.06	7,000	4
2024-06-03	Reardon, Tighe	Officer	Acting Chief Financial Officer	Indirect	Sale	822,721	54.75	$45,043,974.75	633,673	4
2024-06-03	Avalon, Ventures Xi, L.P.…	TenPercentOwner	-	Direct	Sale	677,279	54.75	$37,081,025.25	3,271,216	4
2024-06-03	Lichter, Jay	Director,TenPercentOwner	-	Indirect	Sale	1,500,000	54.75	$82,125,000.00	633,673	4
2023-11-13	Avalon, Ventures Xi, L.P.…	TenPercentOwner	-	Indirect	Purchase	849,854	5.87	$4,988,642.98	849,854	4
2023-11-13	Reardon, Tighe	Officer,TenPercentOwner	Acting Chief Financial Officer	Indirect	Purchase	849,854	5.87	$4,988,642.98	849,854	4
2023-11-13	Lichter, Jay	Director,TenPercentOwner	-	Indirect	Purchase	849,854	5.87	$4,988,642.98	849,854	4
2023-07-19	Ra, Capital Nexus Fund Ii…	Director,TenPercentOwner	-	Indirect	Purchase	495,008	12.46	$6,167,799.68	8,117,246	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

92.88%

Inst. Shares: 58,203,425

Shares Outstanding: 62,665,717

2025-12-31

98.29%

Inst. Shares: 60,908,015

Shares Outstanding: 61,966,999

2025-09-30

100.94%

Inst. Shares: 62,607,422

Shares Outstanding: 62,023,685

2025-06-30

101.81%

Inst. Shares: 63,023,004

Shares Outstanding: 61,902,411

2025-03-31

103.44%

Inst. Shares: 63,916,513

Shares Outstanding: 61,791,721

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	58,203,425	62,665,717	92.88%
2025-12-31	60,908,015	61,966,999	98.29%
2025-09-30	62,607,422	62,023,685	100.94%
2025-06-30	63,023,004	61,902,411	101.81%
2025-03-31	63,916,513	61,791,721	103.44%
2024-12-31	61,188,237	53,751,480	113.84%
2024-09-30	44,442,363	54,628,670	81.35%
2024-06-30	43,513,001	54,451,666	79.91%
2024-03-31	41,519,031	49,049,741	84.65%
2023-12-31	33,330,072	44,016,283	75.72%
2023-09-30	35,010,214	45,708,649	76.59%
2023-06-30	30,571,219	41,836,238	73.07%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Janux Therapeutics, Inc. (JANX) — SEC Financial Statements & Analysis

Janux Therapeutics, Inc. (JANX) is a pharmaceutical preparations company, incorporated in DE. Janux Therapeutics, Inc. trades on Nasdaq as: JANX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Janux Therapeutics, Inc. reported a 5366.97% year-over-year revenue growth, a Debt-to-Equity ratio of 0.09x, a Price-to-Sales (P/S) ratio of 40.28x (TTM), a Price-to-Book (P/B) ratio of 1.04x (TTM), at a market cap of $966.72M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 5366.97%
Debt To Equity: 0.09x
P/S TTM: 40.28x
P/B TTM: 1.04x
Market Cap: $966.72M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Janux Therapeutics, Inc. in?

Janux Therapeutics, Inc. (JANX) operates in the Pharmaceutical Preparations industry.

What is JANX's market cap?

Janux Therapeutics, Inc. (JANX) has a market capitalization of $966.72M as of 2026-06-30.

What exchange does JANX trade on?

Janux Therapeutics, Inc. (JANX) trades on the Nasdaq.

Where is Janux Therapeutics, Inc. incorporated?

Janux Therapeutics, Inc. is incorporated in DE.